Sale!

Carbamazepine Antibody Polyclonal

$395.00 $295.00

Catalog #: A2010024 – 0.25 mg
Carbamazepine is an anti-seizure drug belonging to the class of anti-epileptics and anti-convulsants. This sheep polyclonal antibody is specific to carbamazepine and does not significantly cross-react with carbamazepine-derived metabolites. Bulk pricing and biotinylation services are available.

Live Enquiry about this product via Text/SMS: 1-858-900-3210 (8 am – 8 pm PST)

In stock

SKU: A2010024 Category: Tags: ,

Description

Carbamazepine Antibody

Product Data Sheet Download Data Sheet
MSDS Download MSDS
Catalog number: A2010024
Lot number: 0119A0024
Expiration date: 4/15/23
Package Size: 0.25 mg
Other names: Antibody to Carbamazepine
Supplied as: Liquid Solution
Concentration: 4 mg/mL
Type: Ig
Host: Sheep
Specificity: Carbamazepine (100%), Carbamazepine 10,11-epoxide (11%)
Cross-reaction: Carbamazepine 10,11-epoxide (11%), 10,11-Dihydro-10-hydroxycarbamazepine (1%)
Purification: Purified
Immunogen Carbamazepine-BSA
Preservative: 0.05% sodium azide
Storage: 2-8°C (short term), -20°C (long term). Avoid repeated freeze-thaw.

 

References

  • 4-Substituted carbamazepine derivatives: Conformational analysis and sodium channel-blocking properties. Kanase Y, Kitada T, Tabata H, Makino K, Oshitari T, Ohashi H, Yoshinaga T, Natsugari H, Takahashi H. Bioorg Med Chem. 2018 May 15;26(9):2508-2513.
  • Chemometric Models for Quantification of Carbamazepine Anhydrous and Dihydrate Forms in the Formulation. Barakh Ali SF, Rahman Z, Dharani S, Afrooz H, Khan MA. J Pharm Sci. 2019 Mar;108(3):1211-1219.
  • Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. Post RM, Ketter TA, Uhde T, Ballenger JC. CNS Drugs. 2007;21(1):47-71.
  • Alterations in Pharmacokinetics of Orally Administered Carbamazepine in Rats Treated with Sodium alginate: Possible Interaction between Therapeutic Drugs and Semi-solid Enteral Nutrients. Nagai K, Omotani S, Ito A, Nishimura I, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Drug Res (Stuttg). 2019 Feb;69(3):168-172.
  • Presence and fate of carbamazepine, oxcarbazepine, and seven of their metabolites at wastewater treatment plants. Leclercq M, Mathieu O, Gomez E, Casellas C, Fenet H, Hillaire-Buys D. Arch Environ Contam Toxicol. 2009 Apr;56(3):408-15.
  • Determination of carbamazepine and 12 degradation products in various compartments of an outdoor aquatic mesocosm by reliable analytical methods based on liquid chromatography-tandem mass spectrometry. Daniele G, Fieu M, Joachim S, Bado-Nilles A, Beaudouin R, Baudoin P, James-Casas A, Andres S, Bonnard M, Bonnard I, Geffard A, Vulliet E. Environ Sci Pollut Res Int. 2017 Jul;24(20):16893-16904.
  • Effects of semi-solidification of enteral nutrients on the pharmacokinetic behavior of orally administered carbamazepine in rats. Nagai K, Omotani S, Shibano M, Kobayashi A, Ito A, Nishimura I, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Int J Med Sci. 2019 Sep 7;16(9):1283-1286.